Discontinued — last reported Q3 '19
An increase indicates higher contract value and stronger demand for the company's proprietary technology or intellectual property. A decrease may suggest smaller deal sizes or a shift toward different revenue models.
This metric represents the total contract value allocated to upfront licensing fees and prepaid revenues as defined with...
Comparable to 'Total Contract Value' or 'Upfront Consideration' reported by other biotechnology and diagnostic firms engaged in out-licensing their proprietary platforms.
ntra_segment_upfront_licensing_fees_and_prepaid_revenues_agreement_transaction_price